EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis

Solène M Laville iD, Cécile Couchoud iD, Marc Bauwens, Henri Vacher-Coponat, Gabriel Choukroun, Sophie Liabeuf iD, REIN Collaborators

Nephrology Dialysis Transplantation · 2024

DOI: 10.1093/ndt/gfae042 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Solène M Laville und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacoepidemiology Unit, Pharmacology Department, Amiens University Hospital, Amiens, France. Hauptthemen laut MEDLINE: Renal Dialysis, Vitamin K, Anticoagulants, Registries. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials of direct oral anticoagulants (DOAC) are scarce and inconclusive in patients who are receiving dialysis, for whom DOAC are not labelled in Europe. In a French nationwide registry study of patients on chronic dialysis, we compared the effectiveness and safety of off-label DOAC use vs approved vitamin K antagonist (VKA).

Methods

Data on patients on dialysis were extracted from the French Renal Epidemiology and Information Network (REIN) registry and merged with data from the French national healthcare system database (Système National des Données de Santé, SNDS). Patients on dialysis who had initiated treatment with an oral anticoagulant between 1 January 2012 and 31 December 2020, were eligible for inclusion. The primary safety outcome was the occurrence of major bleeding events and the primary effectiveness outcome was the occurrence of thrombotic events. Using propensity score–weighted cause-specific Cox regression, we compared the safety and effectiveness outcomes for DOAC and VKA.

Results

A total of 8954 patients received an oral anticoagulant (483 DOAC and 8471 VKA) for the first time after the initiation of dialysis. Over a median (interquartile range) follow-up period of 1.7 (0.8–3.2) years, 2567 patients presented a first thromboembolic event and 1254 patients had a bleeding event. After propensity score adjustment, the risk of a thromboembolic event was significantly lower in patients treated with a DOAC than in patients treated with a VKA {weighted hazard ratio (wHR) [95% confidence interval (CI)] 0.66 (0.46; 0.94)}. A non-significant trend toward a lower risk of major bleeding events was found in DOAC-treated patients, relative to VKA-treated patients [wHR (95% CI) 0.68 (0.41; 1.12)]. The results were consistent across subgroups and in sensitivity analyses.

Conclusions

In a large group of dialysis patients initiating an oral anticoagulant, the off-label use of DOACs was associated with a significantly lower risk of thromboembolic events and a non-significantly lower risk of bleeding, relative to VKA use. This provides reassurance regarding the off-label use of DOACs in people on dialysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisVitamin KAnticoagulantsRegistriesHumansFemaleMaleAgedAdministration, OralMiddle AgedHemorrhageKidney Failure, ChronicFranceFactor Xa Inhibitors

Stichwörter der Autor:innen

ESKDatrial fibrillationdialysisdirect oral anticoagulantvitamin K antagonists

Substanzen

Vitamin KAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Pharmacoepidemiology Unit, Pharmacology Department, Amiens University Hospital, Amiens, France.
  • MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.
  • Renal Epidemiology and Information Network (REIN) Registry, Agence de la biomédecine, Saint Denis La Plaine, France.
  • Department of Nephrology and Haemodialysis, Poitiers University Hospital, Poitiers, France.
  • Department of Nephrology and Kidney Transplantation, Felix Guyon Hospital, Saint-Denis, La Réunion, France.
  • Nephrology Dialysis and Transplantation Department, Amiens University Hospital, Amiens, France.

ORCID-Profile: Solène M Laville, Cécile Couchoud, Sophie Liabeuf

Zitieren

APA

Laville, S. M., Couchoud, C., Bauwens, M., Vacher-Coponat, H., Choukroun, G., Liabeuf, S., & REIN Collaborators (2024). Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae042

Vancouver

Laville SM, Couchoud C, Bauwens M, Vacher-Coponat H, Choukroun G, Liabeuf S, et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfae042

BibTeX
@article{Laville2024,
  author = {Laville, Solène M and Couchoud, Cécile and Bauwens, Marc and Vacher-Coponat, Henri and Choukroun, Gabriel and Liabeuf, Sophie and REIN Collaborators, REIN Collaborators},
  title = {Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  doi = {10.1093/ndt/gfae042}
}
Kostenlos starten →